29th EAHP Congress highlights Biopharmaceuticals are complex biological molecules that require careful storage and handling to ensure medication integrity. They are especially sensitive to mechanical stress and shaking,… read more.
The NHS could prevent thousands more heart attacks and strokes every year by offering everyone in the UK aged 50 and over a single “polypill” combining a statin… read more.
Eton Pharmaceuticals Inc announced that it has launched Galzin (zinc acetate) capsules. Galzin is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially… read more.
The European Medicines Agency (EMA) has recommended four new products for approval, and extended the use of sixteen other drugs. The decisions, which brings to 12 the total… read more.
The use of the anti-contraction (tocolytic) drug atosiban in cases of threatened premature birth after 30 weeks of pregnancy is not more effective than placebo at reducing poor… read more.
Sandoz, announces the launch of Pyzchiva (ustekinumab-ttwe) in the US. Developed by Samsung Bioepis Co., Ltd., and marketed by Sandoz, Pyzchiva has been approved by the FDA for… read more.
Generic drugs manufactured in India are linked to significantly more “severe adverse events” for patients who use them than equivalent drugs produced in the United States, a new… read more.
Repurposing amlodipine, a commonly used blood pressure medicine, could help manage attention-deficit/ hyperactivity disorder (ADHD) symptoms, according to an international study involving the University of Surrey. In a… read more.
Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems. PPIs are activated in the acid-producing cells of… read more.
Pharmacogenomics – an individual’s genetic response to medications – is an increasingly important strand of personalised healthcare but little is known about the public’s views on it. Researchers… read more.
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart… read more.
A meta-analysis evaluating bleeding risks among atrial fibrillation (AF) patients treated with therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) indicates that rates of major… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
